Shareholder rights law firm Johnson & Weaver, LLP reminds investors of
the September 16, 2014 lead plaintiff deadline in a securities class
action lawsuit filed by the firm against Prosensa Holding N.V.
(NASDAQ:RNA). The class action lawsuit was filed in the United States
District Court for the Southern District of New York on behalf of the
class (the "Class"). Those purchasers of the ordinary common shares of
Prosensa pursuant and/or traceable to the Company's initial public
offering ("IPO") on or about June 28, 2013 and suffered significant
losses are encouraged to contact Johnson & Weaver regarding your legal
Prosensa is a biotechnology company engaged in the discovery and
development of RNA-modulating therapeutics for the treatment of genetic
disorders. The Company's first and lead product candidate was
drisapersen, which Prosensa was developing in collaboration with
GlaxoSmithKline to address a variety of mutations resulting in
inadequate production of dystrophin - a protein necessary for muscle
Additional Information about the Lawsuit:
On September 20, 2013, less than three months after Prosensa's June 2013
IPO, the Company issued a joint press release with GlxoSmithKline,
disclosing that drisapersen had not met the primary endpoint in the
Phase III study. According to the press release, "There was no treatment
difference in key secondary assessments of motor function: 10-meter
walk/run test, 4-stair climb and North Star Ambulatory Assessment."
On this news, Prosensa stock declined approximately 70 percent, or
$16.86 per share, on unusually heavy trading volume, to close on
September 20, 2013 at $7.14 per share.
Prosensa and certain of its executives are charged with issuing a series
of materially false and misleading statements during the Class Period,
violating federal securities laws.
The Complaint alleges that the Registration Statement in Prosensa's 2013
IPO contained materially false and/or misleading statements and/or
omitted material information concerning the development status of
drisapersen, the drug's Phase II and Phase III clinical studies, and the
prospects for drisapersen's regulatory approval.
Plaintiff seeks to recover damages on behalf of all purchasers of
Prosensa publicly traded securities during the Class Period. If you wish
to serve as a lead plaintiff, you must move the Court no later than
September 16, 2014. If you wish to discuss this action, have any
questions concerning this notice, or your rights or interests, please
contact lead analyst Jim Baker (email@example.com)
at 619-814-4471. If you email, please include your phone number.
Johnson & Weaver, LLP is a nationally recognized shareholder rights law
firm with offices in California, New York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more information
about the firm and its attorneys, please visit http://www.johnsonandweaver.com.
[ Back To NFVZone's Homepage ]